All In Biotech

Drug Trial Radar · NCT03658070

A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours

A Phase I Open and Multiple Ascending Dose Study to Assess the Safety、Tolerability、Pharmacokinetics and Pharmacodynamic Characteristics of XY0206 in Subjects With Chinese Advanced or Metastatic Solid Tumours

Last checked: Nov 19, 2026Latest source record: Aug 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

34

Planned (sponsor's estimate)

Start

Dec 19, 2018

Primary completion

Dec 2020

Study completion Dec 2020

Sponsor

Sponsor type
Industry
Collaborators
Tigermed Consulting Co., Ltd
First posted
Sep 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. To observe the safety and tolerability of oral XY0206 in patients with advanced/metastatic malignant solid tumor in China, and observe the drug dose limiting toxicity (DLT) to establish the maximum tolerated dose (MTD) in humans. 2. To investigate the pharmacokinetic (PK) characteristics, pharmacodynamics (PD) characteristics, and PK/PD correlation of single and multiple doses of XY0206 in patients with advanced/metastatic malignant solid tumors to provide dose selection basis for clinical studies; 3. To evaluate the effect of standard meal on main PK parameters of XY0206; 4. To determine the metabolites of XY0206 in patients with advanced/metastatic malignant solid tumor. 5. To explore the correlation between PK and QTcF. 6. Preliminary investigates the effectiveness of XY0206 in patients with advanced/metastatic malignant solid tumors.

Conditions

  • Advanced or Metastatic Solid Tumours

Interventions

  • XY0206Drug

    Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  2. AETime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  3. ADRTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  4. SAETime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  5. Blood routineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  6. Urine routineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  7. Stool routineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  8. Blood biochemistryTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  9. Coagulation functionTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  10. 12 lead ecgTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  11. Body temperatureTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  12. Blood pressureTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  13. Heart rateTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  14. BreathingTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  15. General conditionTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  16. SkinTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  17. HeadTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  18. EyesTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  19. EarsTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  20. NoseTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  21. ThroatTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  22. HeartTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  23. LungTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  24. ChestTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  25. AbdomenTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  26. LimbsTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  27. NervesTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  28. Back/spineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  29. Lymph nodesTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Hainan Medical College

    Haikou, Hainan, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.